Statement from Novartis Gene Therapies: OAV301 program for familial ALS caused by SOD1 mutation

lesturner Foundation Blog

Please see summary below from Novartis Gene Therapies on the OAV301 program for familial ALS caused by the SOD1 mutation: Novartis Gene Therapies (formerly AveXis) deeply appreciates the collaboration and support of the amyotrophic lateral sclerosis (ALS) community. Our ALS …